KCM
ORKA

Kathmere Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Kathmere Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2
Closed – – 418
2020
Q4 		$0 Hold
2
– – ﹤0.01% 456
2020
Q3 		$0 Buy
+2
New +$141 ﹤0.01% 401

Other funds holding ORKA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Kathmere Capital Management's ORKA Position: Q1 2021 in Review

Kathmere Capital Management sold out of Oruka Therapeutics (ORKA) in Q1 2021, closing a stake of 2 shares.

Kathmere Capital Management first reported a position in ORKA in Q3 2020 and held it in 2 quarters. The position peaked at $0 in Q4 2020. 17 funds tracked by Wall St. Rank hold ORKA as of Q1 2021.

  • Kathmere Capital Management reported no remaining Oruka Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Kathmere Capital Management sold 2 Oruka Therapeutics shares in Q1 2021.
  • Kathmere Capital Management first reported a position in Oruka Therapeutics in Q3 2020 and held it in 2 quarters.
  • Kathmere Capital Management's Oruka Therapeutics position peaked at $0 in Q4 2020.
  • 17 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2021.

Based on Kathmere Capital Management's 13F filing for Q1 2021, filed 7 May 2021.